Search Results
Jul 06, 2026, 11:19 ET A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
include Xencor (NASDAQ: XNCR), CytomX Therapeutics (NASDAQ: CTMX), Zymeworks (NASDAQ: ZYME), and Nurix Therapeutics (NASDAQ: NRIX), each distinct, and none a proxy for GT Biopharma.Putting AI to Work on the Hardest Part of Drug DesignThe core of the June
More news about: American News Group
Jan 14, 2026, 10:52 ET Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
registration-ready assets is driving the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ: ONCY), Nurix Therapeutics (NASDAQ: NRIX), Erasca (NASDAQ: ERAS), Foghorn Therapeutics (NASDAQ: FHTX), and ORIC Pharmaceuticals (NASDAQ: ORIC).
More news about: Equity Insider
Oct 17, 2025, 09:00 ET Precision Oncology Approaches Drive $312B Market Transformation
immune activation platforms, and bispecific antibodies positions GT Biopharma, Inc. (NASDAQ: GTBP), Nurix Therapeutics, Inc. (NASDAQ: NRIX), GRAIL, Inc. (NASDAQ: GRAL), C4 Therapeutics, Inc. (NASDAQ: CCCC), and Pfizer, Inc. (NYSE: PFE).
More news about: USA News Group